Melanoma in situ (controls excluding all cancers)

CD2_INSITU_MELANOMA_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D03
Cause of death: ICD-10 D03

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

980

diagram downward connector
CD2_INSITU_MELANOMA_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D00-D09
Name in latin Melanoma in situ

Similar endpoints

List of similar endpoints to Melanoma in situ (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 980 494 486
Unadjusted prevalence (%) 0.24 0.21 0.27
Mean age at first event (years) 66.71 63.86 69.60

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.05 2.53 [1.36, 4.71] 3.4e-3 93
15 years 0.01 1.35 [0.71, 2.59] 3.6e-1 42
5 years 0.00 2.12 [1.11, 4.05] 2.3e-2 35
1 year 0.00 3.91 [1.91, 8.00] 1.9e-4 13

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_INSITU_MELANOMA_EXALLC – Melanoma in situ (controls excluding all cancers)
GWS hits: 2

Survival analyses between endpoints

Plot

before Melanoma in situ (controls excluding all cancers)
after Melanoma in situ (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Melanoma in situ (controls excluding all cancers)

Endpoint not on priority list, no data to show.